Respiri Ltd
ASX:RSH
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.022
0.096
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Respiri Ltd
Net Issuance of Common Stock
Respiri Ltd
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
R
|
Respiri Ltd
ASX:RSH
|
Net Issuance of Common Stock
AU$8.8m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
19%
|
CAGR 10-Years
-6%
|
|
|
ImpediMed Ltd
ASX:IPD
|
Net Issuance of Common Stock
AU$58k
|
CAGR 3-Years
-85%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-41%
|
|
|
C
|
Cyclopharm Ltd
ASX:CYC
|
Net Issuance of Common Stock
AU$24m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cochlear Ltd
ASX:COH
|
Net Issuance of Common Stock
-AU$45.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Net Issuance of Common Stock
AU$16.7m
|
CAGR 3-Years
15%
|
CAGR 5-Years
62%
|
CAGR 10-Years
N/A
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Net Issuance of Common Stock
AU$15.2m
|
CAGR 3-Years
19%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
Respiri Ltd
Glance View
Respiri Ltd. engages in research, development, and commercialization of medical devices and the production of mobile health applications for management of asthma and related chronic respiratory diseases. The company is headquartered in Melbourne, Victoria. The company went IPO on 2000-07-14. The firm's segments include Australia and Israel. The Australia segment is engaged in research, development and commercialization of medical devices, and the production of mobile health applications in Australia. The Israel segment is engaged in research, development and commercialization of medical devices, and the production of mobile health applications in Israel. The firm has developed a wheezo, which is an eHealth Saas platform that uses a device and app to measure, record and assist asthma monitoring. Its device and app make up a cloud-based mobile health platform that records wheeze and other clinically relevant symptoms and signs of asthma.
See Also
What is Respiri Ltd's Net Issuance of Common Stock?
Net Issuance of Common Stock
8.8m
AUD
Based on the financial report for Jun 30, 2024, Respiri Ltd's Net Issuance of Common Stock amounts to 8.8m AUD.
What is Respiri Ltd's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 10Y
-6%
Over the last year, the Net Issuance of Common Stock growth was 141%. The average annual Net Issuance of Common Stock growth rates for Respiri Ltd have been -12% over the past three years , 19% over the past five years , and -6% over the past ten years .
You don't have any saved screeners yet
